The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).
 
David A. Reardon
Honoraria - Abbvie; Cavion; Genentech/Roche; Merck; Midatech Pharma; Momenta Pharmaceuticals; Novartis; Novocure; Regeneron; Stemline Therapeutics
Consulting or Advisory Role - Cavion; Genentech/Roche; Merck; Momenta Pharmaceuticals; Novartis; Novocure; Regeneron; Stemline Therapeutics
Speakers' Bureau - Genentech/Roche; Merck
Research Funding - Celldex (Inst); Incyte (Inst)
 
John Frederick De Groot
Employment - Helsinn Therapeutics (I)
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Celldex; Deciphera; Foundation Medicine; Genentech/Roche; Vascular Biogenics
Research Funding - Deciphera; EMD Serono; Lilly; Novartis; Sanofi
 
Howard Colman
Consulting or Advisory Role - CytRx Corporation; Genentech; Novocure; Omniox; Oxigene; Roche; Upsher-Smith
Research Funding - Newlink Genetics; Plexxikon
 
Justin T Jordan
Consulting or Advisory Role - Schlesinger Associates
 
Mariza Daras
Travel, Accommodations, Expenses - Lilly
 
Jennifer Leigh Clarke
Research Funding - Agios (Inst); Genentech/Roche (Inst); Novartis (Inst)
 
Phioanh Leia Nghiemphu
Consulting or Advisory Role - Novocure
Research Funding - Genentech/Roche; GlaxoSmithKline
 
Sarah C. Gaffey
No Relationships to Disclose
 
Katherine B. Peters
Consulting or Advisory Role - Novocure
Research Funding - Agios; Eisai; Genentech; Merck; VBL Therapeutics